The diabetes care announcement marks the latest healthcare foray by the retail giant.
Walmart announced the launch of its private brand analog insulin through the ReliOn brand Tuesday morning.
The company stated that analog insulin vials will be available for $72.88, while FlexPen® will be available for $85.88, offering customers significant savings compared to branded analog insulin products. Customers will need a prescription to purchase the products.
Walmart's new private label ReliOn™ NovoLog® Insulin, an insulin aspart injection, is manufactured by Novo Nordisk and will be available in stores this week, followed by a rollout to Sam's Club locations in mid-July.
"We know many people with diabetes struggle to manage the financial burden of this condition, and we are focused on helping by providing affordable solutions," Dr. Cheryl Pegus, executive vice president of Walmart Health & Wellness, said in a statement. "We also know this is a condition that disproportionately impacts underserved populations. With ReliOn NovoLog® insulin, we’re adding a high-quality medication for diabetes to the already affordable ReliOn line of products and continuing our commitment to improve access and lowering cost of care."
The diabetes care announcement marks the latest healthcare foray by the retail giant.
In May, Walmart announced plans to acquire MeMD, a Phoenix-based telemedicine provider, in a deal set to close in the coming months.
In October 2020, Walmart and Clover Health, the Nashville-based technology-oriented Medicare Advantage company, announced that the two companies would jointly offer two Medicare Advantage products to seniors in Georgia in 2021.
Related: Clover Health President Discusses Recent IPO, MA Growth Plans
Jack O'Brien is the Content Team Lead and Finance Editor at HealthLeaders, an HCPro brand.
Photo credit: HDR image, Walmart store highway sign, US American flag waving - Saugus, Massachusetts USA - April 29, 2015 / Editorial credit: QualityHD / Shutterstock.com